DelveInsight’s, “Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024” report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the ...

DelveInsight's,“ Diffuse Intrinsic Pontine Glioma Pipeline Insight, 2025 ” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Diffuse Intrinsic Pontine Glioma ...

NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John M. Goldberg, MD as fractional Chief Medical Officer (CMO) to advance development of its Large Surface Area ...

RALEIGH, N.C., Jan. 31, 2023 (GLOBE NEWSWIRE) -- FLAG Therapeutics, Inc., announced today that FLAG-003, an investigational small molecule therapy for the treatment of Diffuse Intrinsic Pontine Glioma ...

Please provide your email address to receive an email when new articles are posted on . The single-center, dose-escalation study included 12 patients (median age, 9 years; 58% female) with newly ...

Please provide your email address to receive an email when new articles are posted on . A 17-year-old woman with no significant past medical history presented to her primary care physician after ...

LONDON, UK / ACCESSWIRE / December 5, 2019 / Midatech Pharma PLC ("Midatech" or the "Company") (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on delivering innovative oncology and rare ...

Claim: E-mail requests birthday cards for Alyssa Bruno, a 5-year-old girl who is battling diffuse pontine glioma. As many of you are aware, this past school year one of my kindergartners, Alyssa Bruno ...

Diffuse intrinsic pontine glioma is a uniformly lethal malignant tumor of infancy with no effective therapies. A new study reveals that inhibition of JMJD3 has robust antitumor activity in diffuse ...

Diffuse intrinsic pontine gliomas (DIPGs), with a median survival of 9 months, represent the biggest therapeutic challenge in pediatric neuro-oncology. Despite many clinical trials, no major ...